CoChat
Sign Up
Cited by 29Bacteriophages and microbial interactionsBacterial Cancer TherapyVirus-based gene therapy research

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A Novel Bacteriophage with the Potential to Inhibit Fusobacterium nucleatum-Induced Proliferation of Colorectal Cancer Cells

Open access
Lam, Ho Yin Pekkle, Lai, Meng-Jiun, Wang, Pin-Chun, Wu, Wen-Jui, Chen, Li-Kuang, Fan, Hsiang-Wei, Tseng, Chun-Chieh, Peng, Shih-Yi, Chang, Kai-Chih·2025·Antibiotics
DOI 10.3390/antibiotics14010045PMC PMC11760851
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Increasing evidence shows that Fusobacterium nucleatum (F. nucleatum) largely affects colorectal cancer (CRC) growth and progression; therefore, the inhibition of intratumoral F. nucleatum may be one realistic approach to combat CRC. Although antibiotics are helpful in eliminating bacteria, the major problem remains the rise of potential antibiotic-resistant strains and antibiotic-associated adverse effects. Currently, bacteriophage therapy has gained interest because of its high selectivity to bacterial hosts and may become a realistic approach in treating bacteria-associated cancers. Methods: In this study, a new F. nucleatum bacteriophage, ØTCUFN3, was isolated and its biological characteristics were identified. In vitro and in vivo studies were performed to investigate the effect of ØTCUFN3 in combating F. nucleatum-induced CRC growth. Results: By applying ØTCUFN3 to F. nucleatum-induced CRC cell lines, p53+/+, and p53−/− isogenic HCT116 cells, our results revealed an inhibition of CRC proliferation and the expression of epithelial-to-mesenchymal transition (EMT) markers. ØTCUFN3 injection also reduced the growth of F. nucleatum-induced mouse xenografts. Conclusions: Our results demonstrated the use of F. nucleatum bacteriophage against CRC, laying the foundation for the future usage of bacteriophage in cancer treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/antibiotics14010045

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 3 references

Research works printed but not linked: 41

  1. Shang, 2018, Fusobacterium nucleatum and colorectal cancer: A review, World J. Gastrointest. Oncol., 10, 71, 10.4251/wjgo.v10.i3.71 · DOI · Paper page
  2. Amitay, 2017, Fusobacterium and colorectal cancer: Causal factor or passenger? Results from a large colorectal cancer screening study, Carcinogenesis, 38, 781, 10.1093/carcin/bgx053 · DOI
  3. Abed, J., Maalouf, N., Manson, A.L., Earl, A.M., Parhi, L., Emgård, J.E.M., Klutstein, M., Tayeb, S., Almogy, G., and Atlan, K.A. (2020). Colon Cancer-Associated Fusobacterium nucleatum May Originate From the Oral Cavity and Reach Colon Tumors via the Circulatory System. Front. Cell. Infect. Microbiol., 10. · DOI
  4. Wu, 2018, Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis in Mice via a Toll-Like Receptor 4/p21-Activated Kinase 1 Cascade, Dig. Dis. Sci., 63, 1210, 10.1007/s10620-018-4999-2 · DOI
  5. Abed, 2016, Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc, Cell Host Microbe, 20, 215, 10.1016/j.chom.2016.07.006 · DOI · Paper page
  6. Yang, 2017, Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21, Gastroenterology, 152, 851, 10.1053/j.gastro.2016.11.018 · DOI
  7. Luo, K., Zhang, Y., Xv, C., Ji, J., Lou, G., Guo, X., Chen, M., Zhang, Y., Wei, H., and Guo, M. (2019). Fusobacterium nucleatum, the communication with colorectal cancer. Biomed. Pharmacother., 116. · DOI
  8. Queen, 2022, Comparative Analysis of Colon Cancer-Derived Fusobacterium nucleatum Subspecies: Inflammation and Colon Tumorigenesis in Murine Models, mBio, 13, e02991-21, 10.1128/mbio.02991-21 · DOI
  9. Lee, 2021, Differential immune microenvironmental features of microsatellite-unstable colorectal cancers according to Fusobacterium nucleatum status, Cancer Immunol. Immunother., 70, 47, 10.1007/s00262-020-02657-x · DOI · Paper page
  10. Wu, 2019, Autoinducer-2 of Fusobacterium nucleatum promotes macrophage M1 polarization via TNFSF9/IL-1β signaling, Int. Immunopharmacol., 74, 105724, 10.1016/j.intimp.2019.105724 · DOI
  11. Borowsky, 2021, Association of Fusobacterium nucleatum with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment, Clin. Cancer Res., 27, 2816, 10.1158/1078-0432.CCR-20-4009 · DOI
  12. Kim, 2021, Impact of Fusobacterium nucleatum in the gastrointestinal tract on natural killer cells, World J. Gastroenterol., 27, 4879, 10.3748/wjg.v27.i29.4879 · DOI
  13. Ventola, 2015, The antibiotic resistance crisis: Part 1: Causes and threats, Pharm. Ther., 40, 277
  14. Patangia, D.V., Anthony Ryan, C., Dempsey, E., Paul Ross, R., and Stanton, C. (2022). Impact of antibiotics on the human microbiome and consequences for host health. Microbiologyopen, 11. · DOI
  15. Wang, Y., Liu, Z., Chen, Q., Yi, L., Xu, Z., Cai, M., Qin, J., Zhang, Y., Du, G., and Hong, J. (2022). Isolation and characterization of novel Fusobacterium nucleatum bacteriophages. Front. Microbiol., 13. · DOI
  16. Machuca, 2010, Isolation of a novel bacteriophage specific for the periodontal pathogen Fusobacterium nucleatum, Appl. Environ. Microbiol., 76, 7243, 10.1128/AEM.01135-10 · DOI
  17. Kabwe, M., Brown, T.L., Dashper, S., Speirs, L., Ku, H., Petrovski, S., Chan, H.T., Lock, P., and Tucci, J. (2019). Genomic, morphological and functional characterisation of novel bacteriophage FNU1 capable of disrupting Fusobacterium nucleatum biofilms. Sci. Rep., 9. · DOI
  18. Gao, 2020, Antibiotics for cancer treatment: A double-edged sword, J. Cancer, 11, 5135, 10.7150/jca.47470 · DOI
  19. Wang, 2017, Role of tumor microenvironment in tumorigenesis, J. Cancer, 8, 761, 10.7150/jca.17648 · DOI · Paper page
  20. Mima, 2015, Fusobacterium nucleatum and T Cells in Colorectal Carcinoma, JAMA Oncol., 1, 653, 10.1001/jamaoncol.2015.1377 · DOI · Paper page
  21. Bashir, 2016, Fusobacterium nucleatum, inflammation, and immunity: The fire within human gut, Tumour Biol., 37, 2805, 10.1007/s13277-015-4724-0 · DOI
  22. Ye, 2017, Fusobacterium Nucleatum Subspecies Animalis Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors, Cancer Prev. Res., 10, 398, 10.1158/1940-6207.CAPR-16-0178 · DOI
  23. Morsi, H., Golizeh, M., Brosseau, N., Janati, A.I., Emami, E., Ndao, M., and Tran, S.D. (2022). Detection of Fusobacterium nucleatum subspecies in the saliva of pre-colorectal cancer patients, using tandem mass spectrometry. Arch. Oral Biol., 134. · DOI
  24. Li, 2015, P53 mutations in colorectal cancer—Molecular pathogenesis and pharmacological reactivation, World J. Gastroenterol., 21, 84, 10.3748/wjg.v21.i1.84 · DOI
  25. Tahara, 2014, Fusobacterium in colonic flora and molecular features of colorectal carcinoma, Cancer Res., 74, 1311, 10.1158/0008-5472.CAN-13-1865 · DOI · Paper page
  26. Wang, 2023, Targeting p53 pathways: Mechanisms, structures and advances in therapy, Signal Transduct. Target. Ther., 8, 92, 10.1038/s41392-023-01347-1 · DOI · Paper page
  27. Chen, 2022, Mutant p53 in cancer: From molecular mechanism to therapeutic modulation, Cell Death Dis., 13, 974, 10.1038/s41419-022-05408-1 · DOI · Paper page
  28. Borysowski, 2012, Phage as a modulator of immune responses: Practical implications for phage therapy, Adv. Virus Res., 83, 41, 10.1016/B978-0-12-394438-2.00002-5 · DOI
  29. Jun, 2014, Bacteriophage therapy of a Vibrio parahaemolyticus infection caused by a multiple-antibiotic-resistant O3:K6 pandemic clinical strain, J. Infect. Dis., 210, 72, 10.1093/infdis/jiu059 · DOI
  30. Sunagar, 2010, Bacteriophage therapy for Staphylococcus aureus bacteremia in streptozotocin-induced diabetic mice, Res. Microbiol., 161, 854, 10.1016/j.resmic.2010.09.011 · DOI
  31. Gogokhia, 2019, Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis, Cell Host Microbe, 25, 285, 10.1016/j.chom.2019.01.008 · DOI
  32. Duerkop, 2018, Murine colitis reveals a disease-associated bacteriophage community, Nat. Microbiol., 3, 1023, 10.1038/s41564-018-0210-y · DOI
  33. Denk, 2022, Inflammation: The incubator of the tumor microenvironment, Trends Cancer, 8, 901, 10.1016/j.trecan.2022.07.002 · DOI
  34. Egido, J.E., Costa, A.R., Aparicio-Maldonado, C., Haas, P.-J., and Brouns, S.J.J. (2021). Mechanisms and clinical importance of bacteriophage resistance. FEMS Microbiol. Rev., 46. · DOI
  35. Dedrick, 2019, Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus, Nat. Med., 25, 730, 10.1038/s41591-019-0437-z · DOI
  36. Zhvania, P., Hoyle, N.S., Nadareishvili, L., Nizharadze, D., and Kutateladze, M. (2017). Phage Therapy in a 16-Year-Old Boy with Netherton Syndrome. Front. Med., 4. · DOI
  37. Borysowski, 2012, Clinical aspects of phage therapy, Adv. Virus Res., 83, 73, 10.1016/B978-0-12-394438-2.00003-7 · DOI
  38. Roach, 2017, Synergy between the Host Immune System and Bacteriophage Is Essential for Successful Phage Therapy against an Acute Respiratory Pathogen, Cell Host Microbe, 22, 38, 10.1016/j.chom.2017.06.018 · DOI
  39. Pabary, 2016, Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung, Antimicrob. Agents Chemother., 60, 744, 10.1128/AAC.01426-15 · DOI
  40. Chu, D., Lan, J., Liang, L., Xia, K., Li, L., Yang, L., Liu, H., and Zhang, T. (2024). The antibacterial activity of a novel highly thermostable endolysin, LysKP213, against Gram-negative pathogens is enhanced when combined with outer membrane permeabilizing agents. Front. Microbiol., 15. · DOI
  41. Lam, 2022, Resolution of systemic complications in Schistosoma mansoni-infected mice by concomitant treatment with praziquantel and Schisandrin B, Int. J. Parasitol., 52, 275, 10.1016/j.ijpara.2021.11.007 · DOI

Cited by

Sorted by citations

See all 29

Metadata

Authors
Lam, H. Y. P., Lai, M.-J., Wang, P.-C., Wu, W.-J., Chen, L.-K., Fan, H.-W., Tseng, C.-C., Peng, S.-Y., & Chang, K.-C.
Affiliations
Tzu Chi University (TW)
Corresponding author
  • Peng, Shih-Yi
  • Chang, Kai-Chih
ORCID
Venue
Antibiotics
Publisher
MDPI AG
Published
2025-01-07
Volume
14
Issue
1
Pages
45
ISSN
2079-6382 (ISSN-L)
DOI
10.3390/antibiotics14010045
PMC
PMC11760851
OpenAlex
W4406151688
Cited by
29
References
3
Citations by year
2026: 18 · 2025: 11
FWCI
15.29
Type
journal article
Language
en
Open access
Licence
Locations
  • Antibiotics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Science and Technology Council of Taiwan (110-2320-B-320-005-MY3)
Topics
  • Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
phage therapy, Fusobacterium nucleatum, colorectal cancer, phage isolation, tumor-associated bacteria, epithelial-mesenchymal transition, p53, HCT116 cells, xenograft tumor growth, antibiotic resistance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review